Bachem Holding AG
SIX:BANB
Net Margin
Bachem Holding AG
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CH |
|
Bachem Holding AG
SIX:BANB
|
3.5B CHF |
20%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
166.8B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
135.7B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
73.9T KRW |
24%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37B CHF |
10%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
29.3B USD |
19%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
25.6B USD |
9%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
21.8B USD |
22%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
151.7B CNY |
21%
|
|
| US |
|
Waters Corp
NYSE:WAT
|
19.3B USD |
22%
|
Bachem Holding AG
Glance View
In the heart of the Swiss pharmaceutical industry, Bachem Holding AG has carved out a distinct niche as a leading player in the peptide manufacturing landscape. Founded by Peter Grogg in 1971, Bachem has grown from a modest laboratory venture into a global powerhouse with an exceptional focus on peptides and oligonucleotide development. These biomolecules, small chains of amino acids, and nucleotides respectively, play crucial roles in modern therapeutics, acting as key components in drug design for treating various ailments. From its headquarters in Bubendorf, Switzerland, Bachem leverages cutting-edge technologies to enhance the purity and scalability of peptide production, meeting the demand from pharmaceutical and biotechnology companies worldwide. By establishing a robust supply chain and maintaining high standards of quality control, the company ensures the reliability and success of its partnerships. At the core of Bachem's business model is the offering of customized products and services tailored to client-specific needs, ranging from research-grade to commercial-scale production. The company generates revenue through long-term contracts and ongoing relationships with key players in the global pharmaceutical industry. As drug discovery advances, Bachem’s role in providing essential active pharmaceutical ingredients (APIs) becomes increasingly central, facilitating the development of novel therapies. The company also invests heavily in research and development to continuously refine its manufacturing processes and expand its service portfolio. By marrying scientific expertise with strategic foresight, Bachem not only anchors itself in the present pharmaceutical landscape but also positions itself for future growth in the biotechnology sector.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Bachem Holding AG's most recent financial statements, the company has Net Margin of 19.9%.
You don't have any saved screeners yet